Follow on Google News News By Tag Industry News * Biopharmaceutical * More Industries... News By Place Country(s) Industry News
Follow on Google News | The NEI Awards $2.03 Million Commercialization SBIR Grant to AciontThe National Eye Institute awarded a $2.03 million phase IIB grant to Aciont Inc. to fund the clinical development of a non-invasive, passive diffusion-based treatment for uveitis (referred to as DSP-Visulex-TM).
By: Aciont Inc Aciont's Visulex treatment entails a proprietary combination of a pharmaceutical formulation and a scleral lens-shaped topical eye application device that delivers therapeutically relevant doses of drug to intraocular tissues in less than 10 minutes. Aciont completed work under the preclinical proof of concept phase of the grant with the support of research faculty at the University of Utah's departments of pharmaceutics and pharmaceutical chemistry and the John A. Moran Eye Center. “We are humbled that the NEI has awarded Aciont a highly competitive, continuing renewal commercialization grant that will support the clinical development of our novel, non-invasive, ocular drug delivery system,” said John Higuchi, Aciont’s chief executive officer. Higuchi also noted that “The DSP Visulex treatment potentially may address treating a wide variety of diseases of the eye relating to intraocular inflammation whether it entails remedying eye surface indications or posterior eye disease such as diabetic macular edema. The potential collective global market value in ophthalmology using the DSP Visulex treatment is the range in excess of $2 billion.” Dr. Balbir Brar, Aciont’s senior vice president of research and development, added “This continuous funding of the project by the NEI is a testimonial to the unique therapeutic approach that Aciont scientists are pursuing for treating both important and underserved diseases of the eye and we are very thankful for this.” The project described is supported by NIH Award Number R44EY014772- Aciont Inc. is a specialty biopharmaceutical company endeavoring to become the world leader in commercializing localized, non-invasive (topical passive diffusion-based and iontophoretic) Source: Aciont Inc. Contact Information: End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|